子宫内膜癌患者胚系多基因面板检测的应用价值
单中心回顾性队列纳入2012至2021年间接受胚系多基因面板检测的224例子宫内膜癌患者,33例(14.7%,95%CI 10.4-20.1)检出可干预突变,21例(9.4%,95%CI 5.9-14.0)为Lynch综合征相关基因突变;多基因面板检测发现2例(占Lynch综合征病例的9.5%)常规肿瘤组织筛查未识别的Lynch综合征。
要点
- 224例中33例(14.7%)检出可干预胚系突变,21例(9.4%)为Lynch综合征相关基因突变。
- 多基因面板检测发现2例(占Lynch综合征病例9.5%)肿瘤筛查未识别的Lynch综合征。
- 13例(5.8%)检出非Lynch综合征基因的可干预突变,包括CHEK2、BRCA2、ATM、APC、RAD51C、BRCA1。
核心结论
- 作者认为胚系多基因面板检测可行且信息丰富,可发现肿瘤检测未发现的Lynch综合征病例及额外的可干预突变。
研究设计与样本
- 单中心回顾性队列研究,纳入2012至2021年间有遗传检测临床指征并作为标准治疗接受多基因面板检测的子宫内膜癌患者,共224例。
主要发现
- 33例(14.7%,95%CI 10.4-20.1)检出可干预突变。
- 21例(9.4%,95%CI 5.9-14.0)检出Lynch综合征基因突变:MLH1 4例、MSH2 5例、MSH6 7例、PMS2 4例、Epcam-MSH2 1例。
- 多基因面板检测发现2例Lynch综合征(占Lynch综合征病例的9.5%)未被常规肿瘤组织筛查识别。
- 13例(5.8%,95%CI 3.1-9.7)检出至少一个非Lynch综合征基因的可干预突变:CHEK2 6例、BRCA2 2例、ATM 2例、APC 2例、RAD51C 1例、BRCA1 1例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Patients with germline mutations in mismatch repair genes (MLH1, MSH2, MSH6, PMS2) associated with Lynch syndrome (LS) have an increased lifetime risk of endometrial cancer (EC). Multi-gene panel testing (MGPT) is a recent hereditary cancer risk tool enabling next-generation sequencing of numerous genes in parallel. We determined the prevalence of actionable cancer predisposition gene mutations identified through MGPT in an EC patient cohort. METHODS: A single center retrospective cohort study was conducted of patients with EC who had a clinical indication for genetic testing and who underwent MGPT as part of standard of care treatment between 2012 and 2021. Pathogenic mutations were identified and actionable mutations were defined as those with clinical management implications. Additionally, the number of individuals identified with LS was compared between MGPT and tumor-based screening. RESULTS: The study included a total of 224 patients. Thirty-three patients [14.7%, 95% confidence interval (CI) = 10.4-20.1] had actionable mutations. Twenty-one patients (9.4%, 95% CI = 5.9-14.0) had mutations in LS genes (4 MLH1, 5 MSH2, 7 MSH6, 4 PMS2, 1 Epcam-MSH2). MGPT revealed two patients with LS (9.5% of LS cases) not identified through routine tumor-based screening. Thirteen patients (5.8%, 95% CI = 3.1-9.7) had at least one actionable mutation in a non-Lynch syndrome gene (6 CHEK2, 2 BRCA2, 2 ATM, 2 APC, 1 RAD51C, 1 BRCA1). CONCLUSIONS: Germline MGPT is both feasible and informative as it identifies LS cases not found on tumor testing as well as additional actionable mutations in patients with EC.
引用
- Karpel HC, Chern JY, Smith J M, et al. Utility of germline multi-gene panel testing in patients with endometrial cancer. Gynecol Oncol. 2022. PMID: 35483985. doi:10.1016/j.ygyno.2022.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。